Tag : PROGRESSION-FREE SURVIVAL

CONFERENCE UPDATE

HRQoL improvements with pembrolizumab + CCRT and EBRT in high-risk LACC patients in ENGOT-CX11/GOG-3047/KEYNOTE A18
CONFERENCE UPDATE

Validating PFS as a surrogate marker for OS in endometrial cancer treatment assessment: Results from an EORTC-YGCG systemic review
Progression-free survival (PFS) is often utilized as an indicator of the overall survival (OS) of patients with endometrial cancer (EC) to facilitate regulatory approval for novel medical treatments. Nevertheless, its role as a surrogate marker for the survival outcomes of EC patients remains controversial among medical practitioners, with some questioning its reliability and suggesting its inability to reflect the eventual endpoint of the disease. To investigate PFS surrogacy on OS among patients with recurrent and advanced EC, the European Organization For Research and Treatment of Cancer Young Gynaecologic Cancer Group (EORTC-YGCG) conducted a systematic review of randomized phase 2 and 3 clinical trials in advanced/recurrent EC. During ESGO 2024 Congress, Dr. Ramon Yarza from the Royal Marsden Hospital, London, the United Kingdom, shared the findings of this review.